Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. [PDF]
Bichet DG +7 more
europepmc +1 more source
Simultaneous Determination of Lyso-Gb1 and Lyso-Gb3 in Plasma Using Salt-Assisted Liquid-Liquid Extraction Combined with LC-MS/MS. [PDF]
Canbay E +7 more
europepmc +1 more source
Modeling Fabry nephropathy: insights from experimental systems towards precision nephrology. [PDF]
Elsaid H +4 more
europepmc +1 more source
Key considerations for measuring α-galactosidase A activity after long-term migalastat therapy-Avoiding in vitro inhibition effects. [PDF]
Munakata M +4 more
europepmc +1 more source
Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy. [PDF]
Li Y +8 more
europepmc +1 more source
Molecular, Metabolic and Inflammatory Patterns Involved in Pathogenesis of Anderson-Fabry Disease. [PDF]
Simonetta I, Baglio I, Tuttolomondo A.
europepmc +1 more source
Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experience. [PDF]
McCarron EP +7 more
europepmc +1 more source
A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy. [PDF]
Oka M, Suzuki R, Akasaka T.
europepmc +1 more source
Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report. [PDF]
Li XY, Chen QN, Fang JN, Zeng ZC, Pan Y.
europepmc +1 more source

